Polymerized-Type I Collagen Downregulates Inflammation and Improves Clinical Outcomes in Patients with Symptomatic Knee Osteoarthritis Following Arthroscopic Lavage: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial
Figure 1
Primary and secondary measures of efficacy. Clinical evaluation was performed at baseline and every month during the study. The primary endpoints included (a) Lequesne index, (b) patient pain visual analogue scale (VAS), (c) physician pain visual analogue scale (VAS), (d) WOMAC pain subscale, (e) WOMAC stiffness subscale, (f) WOMAC disability subscale, (g) patient’s and (h) physician’s global assessment of disease activity on a 5-point rating scale, global assessment of change in disease activity at the end of the treatment (Likert score: 0 = very poor; 1 = poor; 2 = fair; 3 = well; 4 = very well), (i) consumption of NSAIDs tablets per month. Arrows depict the month in which the treatment reached a compared to baseline, in black for placebo and in red for polymerized collagen group. Results represent mean ± SD. values indicate statistical significant differences between treatment groups.
